Search PubMed⌕ Search

Biomedical subjects

L Brinch

Publications and source records attributed to L Brinch.

At least 73 records · Page 4Linked to original sources
PubMed1991

[Allogeneic bone marrow transplantation in adults. Results after fractionated whole body irradiation and high dosage cyclophosphamide and use of HLA-compatible sibling donors].

We present short and long-term results of allogeneic bone marrow transplantation after hyper-fractionated total body irradiation and high dose cyclophosphamide in ten patients treated for leukaemia during the period 1985-89. Three patients died from complications connected to the transplantation, while seven are living free from leukaemia 18 to 59 months after transplantation (mean 41 months). Two patients need treatment for chronic graft versus host disease. Allogeneic bone marrow transplantation is expensive and risky. Close cooperation between clinicians and laboratory specialists is essential. The treatment increases long term survival and probably cures certain patients with leukaemia. Some of these patients will need treatment for chronic graft versus host disease and other late sequelae.

Adult↗
PubMed1991

[New therapeutic possibilities for leukemia in adults. Indications and progress measures for allogeneic bone marrow transplantation].

Marrow ablation with cytotoxic drugs and/or total body irradiation followed by allogeneic bone marrow transplantation from an HLA-identical sibling cures many patients with acute and chronic myeloid leukaemia. We have obtained good results with this treatment. Up to now the necessary funds to cover the minimal requirements for transplantations in Norway have not been granted. It is now possible to use unrelated, HLA-matched donors, which will more than double the need for allogeneic bone marrow transplantations within a few years. This article discusses indications, results, costs and practical procedures connected to allogeneic bone marrow transplantation for leukaemia in adults.

Adolescent↗
PubMed1990

[Folic acid deficiency can cause severe anemia and pancytopenia].

Pancytopenia is occasionally a consequence of folate deficiency. The most important differential diagnostic considerations are haematologic malignancies, aplastic anaemia and vitamin B12 deficiency. We discuss the problem as exemplified by three patients. Bone marrow examination and determination of blood concentrations of vitamin B12 and folate will give the correct diagnosis.

Adult↗
PubMed1990

[Diagnosis and treatment of solitary plasmacytoma].

Solitary plasmacytomas are rare tumours. We report our experience from 25 solitary osseous and 18 solitary extramedullary plasmacytomas. 41 patients were given high voltage radiotherapy, usually 40 Gy in 20 fractions. Two patients with extramedullary plasmacytoma developed generalized disease, while ten patients with osseous plasmacytoma developed myelomatosis. Extramedullary plasmacytomas are usually cured by adequate local treatment, while in solitary osseous plasmacytomas the prognosis is more dubious.

Adult↗
PubMed1990

[Hairy cell leukemia and Mycobacterium malmoense infection].

We describe a patient with hairy cell leukemia and protracted fever. The patient's condition deteriorated during treatment with alfa Interferon 2b, and his fever persisted. A slight widening of the upper mediastinum appeared after 2.5 months. Mediastinoscopy with lymph node biopsy revealed granulomatous infiltrates with acid-fast bacilli. Cultures of the lymph node material later showed growth of Mycobacterium malmoense. The patient was treated with rifampicin, doxycycline, etambutol and cycloserin for sixteen months and remains afebrile and is gaining weight. His general condition is still improving. An aggressive diagnostic approach is necessary in febrile patients with hairy cell leukemia.

Adult↗
PubMed1990

Extramedullary plasmacytomas and solitary plasma cell tumours of bone.

We describe clinical features and treatment results in 25 patients with solitary osseous (SOP) and 18 patients with solitary extramedullary plasmacytoma (EMP). 41 patients were treated with high-voltage radiotherapy, median 40 Gy in 20 fractions. Surgery was part of the treatment in 21 and chemotherapy in 5 patients. The median age in both groups was 56 years, with a preponderance of males. Myelomatosis developed in 10 SOP and 2 EMP patients, and this development did not correlate with the presence or absence of an M-component at the time of diagnosis of plasmacytoma. The estimated 5- and 10-y survival was 87% and 76% without a statistical difference between SOP and EMP groups. The patients in the SOP group usually died from myelomatosis while EMP patients died from other causes.

Bence Jones Protein↗
PubMed1989

[Treatment of hairy cell leukemia].

Hairy cell leukemia is a rare leukemic variant with a relatively good prognosis. Treatment is indicated when the patient develops symptoms caused by cytopenia. When the spleen is palpable, the primary treatment should be splenectomy. When the spleen is not palpable and/or if the patient relapses after splenectomy, treatment with Alfa-Interferon is indicated. The place of deoxycoformycin in the treatment of hairy cell leukemia has not yet been established.

Adult↗
PubMed1989

[Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].

Adult patients with relapsed and refractory acute myelogenous leukemia usually demand further therapy aimed at achieving remission. The physician knows that life expectancy is limited. Care must be taken to choose a cytotoxic regimen where the potential gains outweigh the risks. Mitoxantrone and cytosine arabinoside were given in combination to 19 patients. Six achieved complete remission and increased survival. The side effects were acceptable.

Adolescent↗
PubMed1989

[Cytogenetic analysis in acute leukemia].

Leukemic cells often show clonal cytogenetic abnormalities. Some of these are strongly associated with certain morphological subgroups and seem to be of prognostic importance. Cytogenetic studies and molecular genetic investigations using recombinant DNA technology have contributed to our understanding of the development of leukemia. This article reviews earlier work on cytogenetic findings in acute leukemia, and adds our own experiences.

Acute Disease↗
PubMed1989

[Experiences of immunologic phenotyping in acute leukemia].

Phenotyping of leukemic cells with monoclonal antibodies usually confirms the morphological classification in acute lymphoblastic and acute myeloid leukemia. Immunological phenotyping gives a more detailed subclassification and may add information on the stage of differentiation of the leukemic cells. This may have prognostic implications, and in the future may influence the choice of treatment modalities. It is not unusual for the leukemic cells to carry both myeloid and lymphoid markers. For such leukemias the prognosis is poor. We describe our experience from immunological phenotyping of 46 acute myeloid and 35 acute lymphoblastic leukemias.

Acute Disease↗
PubMed1989

Late relapses after treatment for acute lymphoblastic leukemia in childhood: a population-based study from the Nordic countries.

Seven late relapses of acute lymphoblastic leukemia occurring 5.5 to 12.3 years after cessation of therapy are reported in 986 patients who had discontinued treatment for leukemia acquired before the age of 15. The study covers patients from the five Nordic countries. Of the 434 patients with ALL who had passed 5 years of follow-up without recurrence, seven have subsequently relapsed so far; an estimated cumulative proportion of 6.9% within the 10 years. In addition, we report a girl 15.9 years old at diagnosis who relapsed 7.3 years after cessation of therapy. These findings confirm that "cure" of acute lymphoblastic leukemia treated in the 1970s cannot be considered definite, even 5 years after discontinuation of therapy.

Adolescent↗
PubMed1988

Leukemia in the central nervous system.

The frequency of central nervous system (CNS) leukemia was studied in patients aged 15-59 with acute leukemia, who had received induction treatment in the years 1971-1986. Twelve out of 103 patients with acute lymphoblastic leukemia (ALL) developed CNS leukemia in spite of prophylaxis consisting of intrathecal methotrexate. Ten out of 217 patients with acute myelogenous leukemia (AML) developed CNS leukemia. None had been given preventive treatment. Leukemic blasts with either M4 or M5 morphology appeared to increase the risk of CNS relapse. Treatment was adjusted to the clinical problem of each patient, but always included intrathecal methotrexate. Median survival after a diagnosis of CNS leukemia was 8 and 6 months in ALL and AML respectively, with bone marrow failure due to hematologic relapse as the leading cause of death. CNS leukemia, if properly treated, does probably not shorten survival. An active approach to diagnosis and treatment is therefore mandatory.

Adolescent↗